Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Best practice & research Clinical endocrinology & metabolism ; 2023.
Article in English | EuropePMC | ID: covidwho-2253722

ABSTRACT

There is an increased interest in the impact of coronavirus disease 19 (COVID-19) on the endocrine system and in particular on the pituitary gland. Over the course of the severe infection with acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there are both acute and delayed effects on pituitary, related to infection and/or treatment. Hypopituitarism, pituitary apoplexy and hypophysitis have been all reported, as well as arginine vasopressin deficiency (diabetes insipidus) and syndrome of inappropriate antidiuretic hormone secretion. Furthermore, patients with acromegaly, Cushing's disease and hypopituitarism are theoretically at increased risk of complications with COVID-19 and need close monitoring. Evidence regarding pituitary dysfunction in patients with COVID-19 continues to be gathered, as the breadth and depth of knowledge also continues to rapidly evolve. This review summarizes data analysis to date on the possible effects of COVID-19 and COVID-19 vaccination on normal pituitary and patients with known pituitary pathology. Though clinical systems were significantly affected, it seems there was no overall loss of biochemical control in patients with certain pituitary pathologies.

2.
Best Pract Res Clin Endocrinol Metab ; : 101752, 2023 Feb 27.
Article in English | MEDLINE | ID: covidwho-2253723

ABSTRACT

There is increased interest related to the impact of coronavirus disease 19 (COVID-19) on the endocrine system and in particular on the pituitary gland. Over the course of the severe infection with acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there are both acute and delayed effects on the pituitary, related to infection and/or treatment. Hypopituitarism, pituitary apoplexy and hypophysitis have been all reported, as well as arginine vasopressin deficiency (diabetes insipidus) and syndrome of inappropriate antidiuretic hormone secretion. Furthermore, patients with acromegaly, Cushing's disease and hypopituitarism are theoretically at increased risk of complications with COVID-19 and require close monitoring. Evidence regarding pituitary dysfunction in patients with COVID-19 continues to be gathered, as the breadth and depth of knowledge also continues to rapidly evolve. This review summarizes data analysis to date on the possible effects of COVID-19 and COVID-19 vaccination on patients with normal pituitary function and patients with known pituitary pathology. Though clinical systems were significantly affected, it seems there is no overall loss of biochemical control in patients with certain pituitary pathologies.

3.
Sci Rep ; 10(1): 21613, 2020 12 10.
Article in English | MEDLINE | ID: covidwho-972258

ABSTRACT

Evidence regarding the relation between SARS-CoV-2 mortality and the underlying medical condition is scarce. We conducted an observational, retrospective study based on Romanian official data about location, age, gender and comorbidities for COVID-19 fatalities. Our findings indicate that males, hypertension, diabetes, obesity and chronic kidney disease were most frequent in the COVID-19 fatalities, that the burden of disease was low, and that the prognosis for 1-year survival probability was high in the sample. Evidence shows that age-dependent pairs of comorbidities could be a negative prognosis factor for the severity of disease for the SARS-CoV 2 infection.


Subject(s)
COVID-19/mortality , Diabetes Mellitus/mortality , Hypertension/mortality , SARS-CoV-2 , Aged , Aged, 80 and over , COVID-19/ethnology , Comorbidity , Diabetes Mellitus/ethnology , Ethnicity , Female , Humans , Hypertension/ethnology , Male , Middle Aged , Obesity/ethnology , Obesity/mortality , Pandemics , Risk Factors , Romania/epidemiology , Romania/ethnology
SELECTION OF CITATIONS
SEARCH DETAIL